KR20040106194A - 고분자형 만노스 결합형 렉틴의 대량 생산방법 및 상기방법으로 제조된 만노스 결합형 렉틴 재조합 단백질의제제화 - Google Patents
고분자형 만노스 결합형 렉틴의 대량 생산방법 및 상기방법으로 제조된 만노스 결합형 렉틴 재조합 단백질의제제화 Download PDFInfo
- Publication number
- KR20040106194A KR20040106194A KR1020030041051A KR20030041051A KR20040106194A KR 20040106194 A KR20040106194 A KR 20040106194A KR 1020030041051 A KR1020030041051 A KR 1020030041051A KR 20030041051 A KR20030041051 A KR 20030041051A KR 20040106194 A KR20040106194 A KR 20040106194A
- Authority
- KR
- South Korea
- Prior art keywords
- mbl
- protein
- transformant
- recombinant
- pres
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1732—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Marine Sciences & Fisheries (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
감염성 질환 | |
Viral disease | HIV |
HBV | |
HCV | |
Influenza A virus | |
Bacterial disease | meningococcal disease |
ischaemic heart disease | |
bacterial pneumonia | |
Fungal and protozoal disease | crytosporidium parvum diarrhoea |
malaria | |
chronic necrotizing plumonary aspergillosis | |
비감염성 질환 | |
systemic lupus erythematosus (SLE) | |
rheumatoid arthritis | |
recurrent miscarriage | |
neoplastic disease |
천연 MBL | 재조합 MBL단백질 | |
C4+ | 0.892 | 0.723 |
C4- | 0 | 0 |
만난 | pre S | |
C4 + | 0.765 | 1.113 |
C4 - | 0.042 | 0.048 |
시료 | OD492 |
PLG-preS + MBL/ 10 mM CaCl2 | 0.535 |
PLG-preS + MBL/ 5 mM EDTA | 0.076 |
PLG-preS | 0.039 |
MBL | 0.037 |
- | 0.038 |
Claims (14)
- pMSG 벡터의NheI 및BglII 제한효소 인식부위에 MBL(Mannose Binding Lectin) 유전자가 발현가능하도록 삽입된 벡터로 형질전환된 형질전환체.
- 제 1항에 있어서, 상기 형질전환체는 CHO, 간세포(hepatocyte) 및 HEK(human embryonic kidney) 세포로 이루어진 군으로부터 선택된 동물세포를 숙주세포로 사용하여 제조된 것인 형질전환체.
- 제 1항에 있어서, 상기 형질전환체는 MBL D1-3 (CHO cell line) KCTC 10472BP인 형질전환체.
- 제 1항 내지 3항중 어느 한 항에 따른 형질전환체로부터 생산된 MBL 재조합 단백질.
- 제 4항의 MBL 재조합 단백질을 유효성분으로 포함하는 보체계 활성화 조성물.
- 제 5항에 있어서, 상기 조성물은 MASP-1(MBL Associated Serine Protease), MASP-2, B형 간염바이러스 pre S, 리포솜 및 PLGA으로 이루어진 군으로부터 1종이상 선택된 것을 더욱 포함하는 것인 조성물.
- (a) B형 간염 바이러스 preS가 부착된 기질을 충진하여 MBL 정제용 컬럼을 제조하고;(b) 상기 컬럼을 평형화시킨 다음 MBL이 포함된 시료를 칼슘 이온존재하에 컬럼에 투입하여 MBL을 상기 B형 간염 바이러스 preS에 특이적으로 결합시키고; 및(c) 상기 MBL이 결합된 컬럼에 EDTA 또는 EGTA가 포함된 완충액을 흘려주어 MBL을 용출시키는 것;을 포함하는 MBL 정제방법.
- 제 4항의 MBL 재조합 단백질을 사람 또는 동물에 투여하여 보체계를 활성화시키는 방법.
- 제 8항에 있어서, 상기 방법은 MASP-1, MASP-2 및 B형 간염바이러스 pre S로 이루어진 군으로부터 1종 이상 선택된 것을 더욱 투여하는 것을 포함하는 것인 방법.
- B형 간염바이러스 pre S, 당쇄화된 단백질, 당쇄화된 펩타이드, 당쇄물(glycosyl moiety) 및 만난으로 이루어진 군으로부터 1종이상 선택된 물질이 부착된 나노 파티클; 및상기 물질에 결합된 MBL 단백질을 포함하는 보체계 활성화용 나노 파티클.
- 제 10항에 있어서, 상기 나노 파티클은 리포솜 또는 PLGA(poly(D,L-lactic-co-glycolic acid))인 것인 나노 파티클.
- 제 10항에 있어서, 상기 나노 파티클은 X-폴리에틸렌 글리콜-Y로 표현되는 링커를 이용하여 상기 물질을 부착하며,상기 X 및 Y는 각각 서로 다르게 하기 화학식 1 내지 4로 표현되는 반응기인 것인 나노 파티클.(화학식 1)(화학식 2)(화학식 3)(화학식 4)
- 제 10항에 있어서, 상기 나노 파티클은 미생물에 의한 감염을 보체계 활성화를 통하여 치료하는 용도로 사용하는 것인 나노 파티클.
- 제 4항의 MBL 재조합 단백질 또는 MBL 야생형 단백질을 유효성분으로 포함하는 사스 예방 및 치료용 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03149970 CN1276079C (zh) | 2003-06-24 | 2003-08-01 | 一种重组高分子型mbl及其制备方法与应用 |
US10/641,816 US7135338B2 (en) | 2003-06-11 | 2003-08-15 | Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20030037511 | 2003-06-11 | ||
KR1020030037511 | 2003-06-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040106194A true KR20040106194A (ko) | 2004-12-17 |
KR100755931B1 KR100755931B1 (ko) | 2007-09-06 |
Family
ID=37380915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030041051A KR100755931B1 (ko) | 2003-06-11 | 2003-06-24 | 고분자형 만노스 결합형 렉틴의 대량 생산방법 및 상기방법으로 제조된 만노스 결합형 렉틴 재조합 단백질의제제화 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100755931B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006046786A1 (en) * | 2004-10-28 | 2006-05-04 | Dobeel Co., Ltd. | Method for the mass production of multimeric mannose binding lectin |
WO2006071102A1 (en) | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9406371D0 (en) | 1994-03-30 | 1994-05-25 | Axis Genetics Ltd | Nematicidal proteins |
KR100408844B1 (ko) * | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
US20040258705A1 (en) * | 2003-02-28 | 2004-12-23 | Antigenics Inc. | Use of lectins to promote oligomerization of glycoproteins and antigenic molecules |
-
2003
- 2003-06-24 KR KR1020030041051A patent/KR100755931B1/ko active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006046786A1 (en) * | 2004-10-28 | 2006-05-04 | Dobeel Co., Ltd. | Method for the mass production of multimeric mannose binding lectin |
WO2006071102A1 (en) | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
US8173599B2 (en) | 2004-12-30 | 2012-05-08 | Dobeel Corporation | Spray-dried collectin compositions and process for preparing the same |
Also Published As
Publication number | Publication date |
---|---|
KR100755931B1 (ko) | 2007-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021508252A (ja) | インターロイキン−2の部分アゴニスト | |
JP4177453B2 (ja) | 組織因子活性インヒビターtfpiおよびtfpi−2のキメラタンパク質および変異体 | |
JP4077876B2 (ja) | ケモカイン結合タンパク質およびその使用 | |
KR20010043602A (ko) | Il-2 선택성 작용제 및 길항제 | |
CN101605557A (zh) | 内切糖苷酶EndoS用于治疗免疫球蛋白G介导的疾病的用途 | |
MX2007000155A (es) | Inmunoglobulina glucosilada e inmunoadhesina que comprende la misma. | |
JP4233214B2 (ja) | ケモカインアンタゴニストとしてのアミノ末端切除型rantes | |
JP2023123763A (ja) | Uti融合タンパク質 | |
CN103313728A (zh) | 治疗中cd89的活化 | |
CN102690354A (zh) | 重组二聚化抗凝血酶III-Fc融合蛋白及其哺乳动物细胞高效表达系统 | |
Tamai et al. | Cloning and expression of flatfish (Paralichthys olivaceus) interferon cDNA | |
KR102651002B1 (ko) | 인터페론-베타 변이체와 항체가 융합된 재조합 단백질 및 이를 포함하는 약학 조성물 | |
EP1812459B1 (en) | Method for the mass production of multimeric mannose binding lectin | |
CN107034201B (zh) | 表观修饰酶setd2的抗病毒作用及其应用 | |
CN101514229A (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物 | |
KR100755931B1 (ko) | 고분자형 만노스 결합형 렉틴의 대량 생산방법 및 상기방법으로 제조된 만노스 결합형 렉틴 재조합 단백질의제제화 | |
CN102093480A (zh) | 重组人血清白蛋白-干扰素α1b融合蛋白及其制备方法 | |
US7311903B2 (en) | Glycosylated human interferon alpha isoform | |
CN101671390B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
US5587457A (en) | Neutrophil stimulating peptides | |
KR101651330B1 (ko) | 세포투과성이 우수한 tat-a20 융합단백질의 제조방법 및 이의 용도 | |
US20060024728A1 (en) | GM-CSF and/or defensin protein expression regulators in epithelial cells comprising ETS transcription factor or gene encoding the same | |
US7135338B2 (en) | Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism | |
JP2021514183A (ja) | 改変免疫調節ペプチド | |
US10172919B2 (en) | Method for treating influenza A virus infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Publication of correction | ||
FPAY | Annual fee payment |
Payment date: 20120828 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130712 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140821 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150825 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160825 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170824 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180823 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190704 Year of fee payment: 13 |